5-脂加氧酶在胃癌中的表达与环氧化酶-2和甲酰肽受体2的关系及其临床意义

doi:10.3969/j.issn.2095-378X.2022.04.003

外科研究与新技术 ›› 2022, Vol. 11 ›› Issue (4): 232-237.doi: 10.3969/j.issn.2095-378X.2022.04.003

5-脂加氧酶在胃癌中的表达与环氧化酶-2和甲酰肽受体2的关系及其临床意义

李庆¹, 徐芬², 雷浪¹, 李里香¹, 郝华^1,3

1.南昌大学第二附属医院病理科,江西南昌 330006;
2.南昌大学第二附属医院全科医学科,江西南昌 330006;
3.同济大学附属杨浦医院病理科,上海 200090

收稿日期:2022-07-20 出版日期:2022-12-28 发布日期:2023-03-20
通讯作者: 郝华,电子信箱： haohua410@126.com
作者简介:李庆（1984—）,女,博士,主治医师,从事临床病理科工作
基金资助:
江西省卫生计生委科技计划（20195204）

Expressions of 5-LOX in gastric carcinoma and its relationships with COX-2 and FPR2 and their clinicopathological implications

LI Qing¹, XU Fen², LEI Lang¹, LI Lixiang¹, HAO Hua^1,3

1. Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China;
2. Department of General Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China;
3. Department of Pathology, Yangpu Hospital, Tongji University, Shanghai 200090, China

Received:2022-07-20 Online:2022-12-28 Published:2023-03-20

摘要/Abstract

摘要： 目的探讨5-脂加氧酶（5-LOX）在胃癌中的表达与5-LOX与环氧化酶-2（COX-2）和甲酰肽受体2（FPR2）的关系及其临床意义。方法采用免疫组织化学法检测70例胃癌组织中3个指标的表达情况,并分析三者间的关系以及临床病理联系。沉默5-LOX基因观察对COX-2及FPR₂的表达有无影响。结果 ≤45岁和>45岁患者5-LOX阳性表达率分别为76.0％和84.4％;肿块直径≤3 cm和>3 cm者阳性表达率分别为82.1％和81.0％;低分化腺癌、中-高分化腺癌和黏液腺癌阳性表达率分别为80.0％、80.0％和90.0％,组间差异均无统计学意义（P>0.05）。在无、有淋巴结转移组中5-LOX阳性率分别为71.8％和93.5％;在Ⅰ~Ⅱ、Ⅲ~Ⅳ期胃癌中5-LOX的阳性表达率分别为75.0％和95.5％,组间差异均有统计学意义（P<0.05）;5-LOX在COX-2阳性和阴性病例中阳性率分别为81.6％和81.0％,组间差异无统计学意义（P>0.05）;5-LOX在FPR2阳性和阴性病例中阳性率分别为78.1％和84.2％,组间差异无统计学意义（P>0.05）。在SGC-7901转染实验中,沉默5-LOX基因对COX-2及FPR₂的表达没有影响。结论 5-LOX在胃癌的侵袭、转移过程中起重要作用,同时靶向5-LOX和COX-2有望成为治疗胃癌的有效手段。

关键词: 胃癌, 5-脂加氧酶, 环氧化酶-2, 甲酰肽受体2

Abstract: Objective To investigate 5-lipoxygenase （5-LOX） expression in gastric carcinoma, its relationships with cyclooxygenase-2 （COX-2） and formyl peptide receptor type 2 （FPR2）, and their clinicopathological implications. Methods Expressions of the above three indexes were detected from 70 gastric carcinoma patients by immunohistochemistry. The relationships among them and clinicopathological features were analyzed. Moreover, whether knockdowning 5-LOX had effects on COX-2 and FPR₂ mRNA expression in SGC-7901 cells was investigated. Results The positive expression rates of 5-LOX were 76.0％ in cases ≤45 years and 84.4％ in cases >45 years; 82.1％ in cases with tumor diameter ≤3 cm and 81.0％ in cases with tumor diameter >3 cm; 80.0％, 80.0％, and 90.0％ in cases of poorly differentiated, middle-highly differentiated, and mucinous adenocarcinoma, respectively, with no significant difference （P>0.05）. The positive expression rates of 5-LOX in cases of gastric carcinoma without and with axillary node metastasis were 71.8％ and 93.5％; in cases at stage Ⅰ-Ⅱ and Ⅲ-Ⅳ, 75.0％ and 95.5％ respectively, with significant difference （P<0.05）. The positive expression rates of 5-LOX in cases of gastric carcinoma with positive COX-2 expression and negative COX-2 expression were 81.6％ and 81.0％ resepctively, without significant difference （P>0.05）, and the values in cases of gastric carcinoma with positive FPR2 expression and negative FPR2 expression were 78.1％ and 84.2％ respectively, without significant difference as well （P>0.05）. Moreover, silencing 5-LOX had no effects on COX-2 and FPR2 mRNA expressions in SGC-7901 cells. Conclusion 5-LOX plays an important role in the invasion and metastasis of gastric carcinoma, and combined targeting 5-LOX and COX-2 would be an effective approach for gastric carcinoma.

Key words: Gastric carcinoma, 5-Lipoxygenase, Cyclooxygenase-2, Formyl peptide receptor type 2

中图分类号:

R735.2

李庆, 徐芬, 雷浪, 李里香, 郝华. 5-脂加氧酶在胃癌中的表达与环氧化酶-2和甲酰肽受体2的关系及其临床意义[J]. 外科研究与新技术, 2022, 11(4): 232-237.

LI Qing, XU Fen, LEI Lang, LI Lixiang, HAO Hua. Expressions of 5-LOX in gastric carcinoma and its relationships with COX-2 and FPR2 and their clinicopathological implications[J]. Surgical Research and New Technique, 2022, 11(4): 232-237.

参考文献

[1] Chen W, Zheng R, Baade PD,et al.Caner statistics in China 2015[J].CA Cancer J Clin, 2016,66(2):115-132.
[2] Luebeck EG, Curtius K, Jeon J, et al.Impact of tumor progerssion on cancer incidence curves[J].Cancer Res, 2013,73(1):1086-1096.
[3] 夏扣柱,张健,窦豆,等.腹腔镜辅助胃癌D2根治术治疗进展期胃癌对比观察[J]. 外科研究与新技术, 2021, 10(2):104-106.
[4] Kennedy TJ, Chan CY, Ding XZ, et al.Lipoxygenase inhibitors for the treatment of pancreatic cancer[J]. Expert Rev Anticancer Ther, 2003,3(4): 525-536.
[5] Lawrence MK, Paul JG, David JB.Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase[J]. World J Gastroenterol, 2014,20(31): 10729-10739 .
[6] Hennig R, Ding XZ, Tong WG, et al.5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue[J]. Am J Pathol, 2002,161(2): 421-428.
[7] Ding XZ, Tong WG, Adrian TE.Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer[J]. Oncology, 2003,65(4): 285-294.
[8] 雒钰杰,徐敏,高雯琬,等. 敲低花生四烯酸 5 脂加氧酶(Alox5)基因促进K562/ADM细胞凋亡[J]. 细胞与分子免疫学杂志, 2017, 33(10):1398-1403.
[9] 徐晓萌,刘纯伦,谢黎. Darbufelone对胃癌SGC-7901细胞裸鼠移植瘤生长的影响[J]. 解放军医学杂志, 2011, 36(2):149-152.
[10] 盛烨华. 5-脂氧合酶基因在胃癌组织中的表达及其临床意义[J]. 交通医学杂志, 2011, 25(6):562-563.
[11] Farrow B, Albo D, Berger DH.The role of the tumor microenvironment in the progression of pancreatic cancer[J]. Surg Res, 2008,149(2): 319-328.
[12] Wang D, Dubois RN.Eicosanoids and cancer[J]. Nat Rev Cancer, 2010, 10(3): 181-193.
[13] Blanke CD, Beason A, Dragovich T, et a1. A phase II trial of celecoxib, irinotecan, 5-flourouracil and leucovorin in patientswith unresectable or metastatic colorectal cancer[J]. Proc Am Soc Clin Oneol, 2002, 21(4): 505-509.
[14] Dannenberg AJ, Subbaramaiah K.Targeting cyclooxygenase-2 in human neoplasia: rationale and promise[J]. Cancer Cell, 2003, 4(6): 431-436.
[15] Liu Y, Tang H, Liu X, et al.Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis[J]. J Leukoc Biol, 2019, 105(1):11-24.
[16] 赵志辉, 程琳, 曹仕琼. 脂氧素A4受体在大肠癌中的表达及临床意义[J].胃肠病学杂志, 2013, 5(5): 425-427.
[17] 王教学, 唐郡, 侯曦露, 等.胃癌组织中甲酰肽受体 2 表达与胃癌患者预后相关性研究[J]. 临床军医杂志, 2018, 46(6): 615-618.
[18] 李远美, 唐郡, 侯曦露, 等. 甲酰肽受体 2 促进胃癌细胞侵袭及转移作用研究[J]. 临床军医杂志, 2018, 46(6): 610-614.
[19] Chang J, Tang N, Fang Q, et al.Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway[J]. Biochem Biophys Res Commun, 2019, 517(1):1-7.

5-脂加氧酶在胃癌中的表达与环氧化酶-2和甲酰肽受体2的关系及其临床意义

Expressions of 5-LOX in gastric carcinoma and its relationships with COX-2 and FPR2 and their clinicopathological implications

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	谢庆国, 孙素花. 舒芬太尼联合右美托咪定对胃癌/结直肠癌根治患者术后镇痛及呼吸的影响[J]. 外科研究与新技术, 2022, 11(2): 97-100.
[2]	李新星, 胡志前. 腹腔镜和机器人在胃癌微创手术中的发展[J]. 外科研究与新技术, 2021, 10(3): 157-161.
[3]	夏扣柱, 张健, 窦豆, 徐明. 腹腔镜辅助胃癌D2根治术治疗进展期胃癌对比观察[J]. 外科研究与新技术, 2021, 10(2): 104-106.
[4]	潘建海, 李中敏, 华健灿. 腹腔镜胃癌根治术中腹腔灌注治疗进展期胃癌的疗效观察[J]. 外科研究与新技术, 2020, 9(1): 17-19.
[5]	陈楷, 吴祖光, 姚仕伟, 邓雪涌, 刘战嬴. 非离断式Roux-en-Y吻合在腹腔镜远端胃癌根治消化道重建中的应用效果分析[J]. 外科研究与新技术, 2020, 9(1): 20-21.
[6]	张世杰, 方万强. 腹腔镜辅助远端胃癌根治术与开腹手术的临床对照分析[J]. 外科研究与新技术, 2019, 8(1): 7-9.
[7]	刘曙光, 袁修翠. 腹腔镜胃癌根治术辅助热灌注化疗治疗进展期胃癌的效果分析[J]. 外科研究与新技术, 2018, 7(4): 232-234.
[8]	郑志华, 黄文场, 苏亦斌, 陈国宝, 刘江睿. 腹腔镜胃癌术后不同消化道重建方法的临床分析[J]. 外科研究与新技术, 2017, 6(2): 82-84.
[9]	慕竹青. 分析卡培他滨联合奥沙利铂治疗老年胃癌患者的临床疗效[J]. 外科研究与新技术, 2015, 4(4): 233-234.
[10]	朱正纲. 提高胃癌外科综合疗效的若干关键性问题[J]. 外科研究与新技术, 2012, 1(1): 4-7.